📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Cronos Stock Rebounds As Earning Point To Improved Long-Term Prospects

Published 2021-03-02, 05:32 a/m

Shares of Cronos Group (NASDAQ:CRON) (TSX:CRON) bounced back yesterday, regaining some of what they lost at the end of last week when the Canadian-based cannabis grower reported its fourth-quarter earnings.

Despite beating analysts’ expectations by posting revenues of US$17.05 million for the three-month period that ended Dec. 31, the company stock dropped approximately 4.5% to close at $10.45 last Friday. It recovered yesterday to close at $11.03, a gain of 5.5% on the day. Analysts had expected revenues to come in at US$13 million.

CRON Daily

The wrinkle for investors was a bigger-than-expected loss of US$75.2 million, which included US$15 million in inventory-related write-downs.

But the write-downs were significantly down from the same period in the previous year, which points to Cronos' production coming into line with demand.

Despite the loss, there was still a lot of positive in the quarterly report, especially when viewed through a longer-term lens. The hike in revenues to attain the US$17.05 million mark represents a more than 130% increase compared with the previous year. This was attributed to better sales in Canada for recreational cannabis, a push into the medical cannabis market in Israel and increased sales in the United States.

In fact, US sales improved by 30%, an impressive marker.

Building on the quarterly metrics, Cronos offered clear direction of where it is headed longer term, with its marked increase in investment in edibles, its move deeper into the Israeli market and a deal with Ulta Beauty (NASDAQ:ULTA) to more aggressively market CBD-based health and beauty products.

“We are poised to build upon the growth we experienced in 2020 as we continue to push cannabinoid innovation and differentiated product offerings under our portfolio of brands,” said president and CEO Kurt Schmidt. “My goals this year will be to focus on building a winning team by fostering a collaborative, performance-driven culture; continue to focus on creating disruptive technology and innovation; grow and develop our brands and strengthen our ability to compete through R&D, strategic global infrastructure and engaging in the legislative process in key markets.”

As the US is poised to legalize cannabis at the federal level, providing the marijuana sector increasing tailwinds, there was yet another indication of the renewed bullish landscape within the sector last week when AdvisorShares announced its AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) hit a significant milestone: surpassing the $1-billion-in-assets-under-management mark.

Launched in September 2020 with only $2.5 million in assets, MSOS was the first US listed ETF focused on US-based cannabis companies, including multi-state operators.

“There's a lot of excitement surrounding the cannabis investment space right now and for a variety of a reasons," said Dan Ahrens, AdvisorShares' chief operating officer and portfolio manager of MSOS. "We firmly believe that the U.S. cannabis market provides a compelling long-term investment opportunity that clearly differentiates itself from other areas of the globe.”

In addition to MSOS, AdvisorShares also manages the AdvisorShares Pure Cannabis (NYSE:YOLO), which was the first US-listed ETF dedicated to cannabis. It focuses on cannabis sector assets from around the globe.

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.